Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for respiratory and immune disorders, will present ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ.
Approved by the U.S. Food and Drug Administration (FDA) on October 5, 2010, ARIDOL is the first new bronchial challenge test in more than two decades. It is used for the assessment of bronchial hyperresponsiveness in patients six years of age and older who do not have clinically apparent asthma. The easy-to-administer, single-use test, which delivers dry powder mannitol to the patient through a hand-held inhaler, can be conducted in a variety of healthcare settings including physician offices and pulmonary function labs. ACAAI meeting attendees can preview ARIDOL and see a demonstration of how it works at the Pharmaxis booth #s1124 and 1126.
ARIDOL is an easy-to-administer, accurate and reproducible bronchial challenge test that requires minimal preparation and administration time. A positive response is indicated when there is a 15% reduction in lung function from baseline.
ARIDOL has been found effective and recognized as generally safe in two Phase III global clinical trials. It is widely recognized by experts as a significant addition to the tools available to help in an overall clinical assessment of asthma. ARIDOL should not be used as a stand-alone tool to assess asthma, but as part of a physician's overall assessment of asthma.